Following weekend speculation and rumors, US pharma giant Pfizer (NYSE: PFE) this morning confirmed that it has entered into a definitive merger agreement with Medivation (Nasdaq: MDVN), to acquire the biopharmaceutical company focused on developing and commercializing small molecules for oncology,
The offer is for $81.50 a share in cash for a total enterprise value of round $14 billion, a preimum of around a third on last Friday's closing share price of $67.16. The boards of directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer’s adjusted diluted earnings per share (EPS) upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.
The agreement appears to thwart the previous announced advances from French pharma major Sanofi (Euronext: SAN), wich offfered around $10 billion.Others said to be in the frame to acquire Medivation included AstraZeneca, Celgene, Gilead Sciences and Merck & Co. Medication's shares rocketed 20.4% to $80.64 in pre-market trading, having risen 39% year-to-date on takeovover speculation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze